<qa>  What is the average survival duration of GBM patients?Significant activity radiographic response rates of approximately 60 has recently been demonstrated in phase II studies in patients with relapsed GBM from the combined use of Irinotecan CPT-11 and bevacizumab. The 6-month progression-free survival rate is 30 and median survival duration is 9 months. The current first line therapy of GBM patients following initial surgical resectiondebulking is the concomitant use of cerebral radiotherapy and the orally available alkylating agent temozolomide, followed by temozolomide for 6 months post-radiotherapy. 